Data from the phase II SUMMIT basket trial of HER tyrosine kinase inhibitor neratinib (Puma Biotechnology Inc.) in patients with HER2 or HER3-mutated tumors across multiple anatomical locations have shown that targeting HER2 can have therapeutic value in tumors beyond breast cancer, but also reaffirmed that for most targeted therapies, the anatomical location as well as the molecular mutation play a role.